Silexion Therapeutics Corp (NASDAQ:SLXN) Short Interest Update

Silexion Therapeutics Corp (NASDAQ:SLXN) was the recipient of a large drop in short interest in December. As of December 15th, there was short interest totaling 78,920 shares, a drop of 29.7% from the November 30th total of 112,215 shares. Based on an average daily volume of 51,039 shares, the days-to-cover ratio is currently 1.5 days. Currently, 2.7% of the company’s stock are sold short. Currently, 2.7% of the company’s stock are sold short. Based on an average daily volume of 51,039 shares, the days-to-cover ratio is currently 1.5 days.

Silexion Therapeutics Stock Performance

NASDAQ SLXN traded down $0.21 during trading hours on Tuesday, hitting $1.87. The company had a trading volume of 105,015 shares, compared to its average volume of 401,512. The company has a quick ratio of 3.97, a current ratio of 3.97 and a debt-to-equity ratio of 0.22. The firm has a market cap of $5.85 million, a P/E ratio of -0.17 and a beta of -0.06. Silexion Therapeutics has a fifty-two week low of $1.80 and a fifty-two week high of $51.75. The business has a fifty day simple moving average of $2.82 and a 200-day simple moving average of $6.28.

Silexion Therapeutics (NASDAQ:SLXN) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($2.88) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.40) by $0.52.

Analyst Ratings Changes

SLXN has been the subject of a number of research analyst reports. Wall Street Zen lowered shares of Silexion Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, December 20th. Litchfield Hills Research initiated coverage on shares of Silexion Therapeutics in a research report on Monday, December 15th. They issued a “buy” rating for the company. Zacks Research upgraded shares of Silexion Therapeutics to a “hold” rating in a research note on Tuesday, December 16th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Silexion Therapeutics in a research note on Wednesday, October 8th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $75.00.

About Silexion Therapeutics

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.